Compare OCUL & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCUL | VRNS |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.9B |
| IPO Year | 2014 | 2014 |
| Metric | OCUL | VRNS |
|---|---|---|
| Price | $12.54 | $33.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | $22.56 | ★ $60.68 |
| AVG Volume (30 Days) | ★ 3.9M | 2.3M |
| Earning Date | 11-04-2025 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $55,783,000.00 | ★ $608,677,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | $11.96 | $15.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.37 |
| 52 Week Low | $5.79 | $30.02 |
| 52 Week High | $16.44 | $63.90 |
| Indicator | OCUL | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 44.35 |
| Support Level | $12.27 | $32.63 |
| Resistance Level | $13.06 | $34.75 |
| Average True Range (ATR) | 0.79 | 1.10 |
| MACD | -0.25 | 0.62 |
| Stochastic Oscillator | 6.23 | 68.43 |
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.